Literature DB >> 10580216

Allergy to protamine sulfate.

R Porsche1, Z R Brenner.   

Abstract

Adverse responses to protamine sulfate have been identified for many years. The antigen-antibody response to protamine sulfate results in a type I anaphylactic reaction. Manifestations of allergic reactions include hypotension, bronchospasm, and skin and mucous membrane reactions. The severity of the adverse responses may vary from mild to causing death. Several potential risk factors for adverse reactions to protamine have been identified, including insulin-dependent diabetes mellitus, vasectomy, allergy to fish, prior exposure to protamine sulfate, and the rate of infusion. A case study is presented, and strategies for improving patient outcomes are discussed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10580216     DOI: 10.1016/s0147-9563(99)70031-2

Source DB:  PubMed          Journal:  Heart Lung        ISSN: 0147-9563            Impact factor:   2.210


  18 in total

1.  Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (II): in vitro evaluation of efficacy and toxicity.

Authors:  L C Chang; J F Liang; H F Lee; L M Lee; V C Yang
Journal:  AAPS PharmSci       Date:  2001

2.  Dendrigraft of Poly-l-lysine as a Promising Candidate To Reverse Heparin-based Anticoagulants in Clinical Settings.

Authors:  Benjamin Ourri; Jean-Patrick Francoia; Gerald Monard; Jean-Christophe Gris; Julien Leclaire; Laurent Vial
Journal:  ACS Med Chem Lett       Date:  2019-05-08       Impact factor: 4.345

Review 3.  Approaches to prevent bleeding associated with anticoagulants: current status and recent developments.

Authors:  Manu Thomas Kalathottukaren; Charles A Haynes; Jayachandran N Kizhakkedathu
Journal:  Drug Deliv Transl Res       Date:  2018-08       Impact factor: 4.617

4.  Low molecular weight protamine as nontoxic heparin/low molecular weight heparin antidote (III): preliminary in vivo evaluation of efficacy and toxicity using a canine model.

Authors:  L M Lee; L C Chang; S Wrobleski; T W Wakefield; V C Yang
Journal:  AAPS PharmSci       Date:  2001

Review 5.  The Indian consensus guidance on stroke prevention in atrial fibrillation: An emphasis on practical use of nonvitamin K oral anticoagulants.

Authors:  Jamshed Dalal; Abhay Bhave; Abraham Oomman; Amit Vora; Anil Saxena; Dhiman Kahali; Fali Poncha; D S Gambhir; Jaydip Ray Chaudhuri; Nakul Sinha; Saumitra Ray; S S Iyengar; Suvro Banerjee; Upendra Kaul
Journal:  Indian Heart J       Date:  2015-11-24

6.  High incidence of antibodies to protamine and protamine/heparin complexes in patients undergoing cardiopulmonary bypass.

Authors:  Grace M Lee; Ian J Welsby; Barbara Phillips-Bute; Thomas L Ortel; Gowthami M Arepally
Journal:  Blood       Date:  2013-02-19       Impact factor: 22.113

7.  Hypersensitivity Reaction to Insulin Glargine and Insulin Detemir in a Pediatric Patient: A Case Report.

Authors:  Jennifer Badik; Jimmy Chen; Kira Letvak; Tsz-Yin So
Journal:  J Pediatr Pharmacol Ther       Date:  2016 Jan-Feb

8.  Incidence and outcomes of protamine reactions in patients undergoing catheter ablation of atrial fibrillation.

Authors:  Karuna Chilukuri; Charles A Henrikson; Darshan Dalal; Daniel Scherr; Edwin C MacPherson; Alan Cheng; David Spragg; Saman Nazarian; Sunil Sinha; Ronald Berger; Joseph E Marine; Hugh Calkins
Journal:  J Interv Card Electrophysiol       Date:  2009-03-05       Impact factor: 1.900

9.  Development of universal antidotes to control aptamer activity.

Authors:  Sabah Oney; Ruby T S Lam; Kristin M Bompiani; Charlene M Blake; George Quick; Jeremy D Heidel; Joanna Yi-Ching Liu; Brendan C Mack; Mark E Davis; Kam W Leong; Bruce A Sullenger
Journal:  Nat Med       Date:  2009-10-04       Impact factor: 53.440

10.  Successful desensitization with human insulin in a patient with an insulin allergy and hypersensitivity to protamine: a case report.

Authors:  Claudia Pföhler; Cornelia Sl Müller; Dirk O Hasselmann; Wolfgang Tilgen
Journal:  J Med Case Rep       Date:  2008-08-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.